The EGF receptor family as targets for cancer therapy

By J. Mendelsohn, J. Baselga. Oncogene, 2000

1,389 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/41731a99a4669856d3528bf5565f760502bf5d98

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. N. Hynes
2. M. Moasser
3. Thomas Holbro
4. R. Agarwal
5. Jan Lankelma
6. E. Stanley
7. J. Condeelis
8. M. Sliwkowski

In Oncology

1. N. Hynes
2. M. Moasser
3. Thomas Holbro
4. J. Condeelis
5. M. Sliwkowski
6. J. Pollard
7. A. Mantovani
8. D. Hanahan

In Radiology, Nuclear Medicine and Imaging

1. N. Hynes
2. M. Moasser
3. Thomas Holbro
4. M. Sliwkowski
5. M. Lacouture
6. Lewis C. Cantley
7. N. Iqbal
8. N. Iqbal

Citations in the corpus

• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (2002, background): “Here, antibodies are selected to inhibit ligand binding and subsequent downstream receptor signaling (Mendelsohn and Baselga, 2000).”
• ErbB receptors: directing key signaling networks throughout life. (2004, background): “Over the past few years, several approaches, including targeting with antagonistic antibodies or small-molecule tyrosine kinase inhibitors, have been developed and are currently under intense clinical investigation (9, 10).”
• Ovarian cancer: strategies for overcoming resistance to chemotherapy (2003, background): “IMC-C225 and EMD-72000 are monoclonal antibodies, whereas ZD-1839 and OSI-774 are small molecules, and all of these inhibit EGFR-mediated signallin”
• Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. (2005, background): “These results are consistent with the wealth of data implicating members of the EGFR family in the progression of carcinomas (3).”
• Cancer: a Systems Biology disease. (2006, background): “Inhibition of constitutive pathways , e.g. by monoclonal antibodies or tyrosine kinase inhibitors, is a strategy that is already employed in clinical trials (Mendelsohn and Baselga, 2000; Sebolt- Leopold, 2000; Shawver et al., 2002).”
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. (2004, background): “of various neoplastic processes, including cell cycle progression, inhibition of apoptosis, angiogenesis, tumor cell motility, invasion and metastasis [5-8].”
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (2007, background): “Readers are referred to several recent excellent reviews of HER family signaling and functions (Mendelsohn and Baselga, 2000; Olayioye et al., 2000; Prenzel et al., 2001; Yarden and Sliwkowski, 2001; Barnes and Kumar, 2004).”
• Targeting RAS signalling pathways in cancer therapy (2003, neutral): “gov/cancerinfo/pdq/treatment/gastric/patient/">stomach carcinomas”